<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039674</url>
  </required_header>
  <id_info>
    <org_study_id>3475-021</org_study_id>
    <nct_id>NCT02039674</nct_id>
  </id_info>
  <brief_title>A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)</brief_title>
  <official_title>A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety, tolerability, and efficacy of
      pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants
      with unresectable or metastatic non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part II, Cohort G: Objective Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II, Cohort H: Objective Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I, All Cohorts: the recommended Phase II dose for pembrolizumab in combination with chemotherapy or immunotherapy</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part II, Cohort G: Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II, Cohort G: Progression-Free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II, Cohort G: Duration of Response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + paclitaxel (200 mg/m^2) + carboplatin (6 mg/mL/minute)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + paclitaxel (200 mg/m^2) + carboplatin (6 mg/mL/minute) + bevacizumab (15 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + pemetrexed (500 mgm^2) + carboplatin (5 mg/mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort D (Pembro + Ipilimumab [I])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 mg/kg) + Ipilimumab (0.3, 1, or 3 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort E (Pembro + Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 mg/kg) + erlotinib (150 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort F (Pembro + Gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 mg/kg) + gefitinib (250 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, Cohort G (C + Pe With/without Pembro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort G1: carboplatin AUC 5 (5 mg/mL/min) + pemetrexed 500 mg/m^2, IV Q3W on Day 1 of each cycle; Cohort G2: carboplatin AUC 5 (5 mg/mL/min) + pemetrexed 500 mg/m^2 + pembrolizumab 200 mg, IV Q3W on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, Cohort H (Pembro + I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab + ipilimumab at recommended Phase II dose determined in Cohort D</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>intravenously (IV) every 3 weeks (Q3W) on Day 1 of each cycle prior to chemo/immunotherapy</description>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
    <arm_group_label>Part I, Cohort D (Pembro + Ipilimumab [I])</arm_group_label>
    <arm_group_label>Part I, Cohort E (Pembro + Erlotinib)</arm_group_label>
    <arm_group_label>Part I, Cohort F (Pembro + Gefitinib)</arm_group_label>
    <arm_group_label>Part II, Cohort G (C + Pe With/without Pembro)</arm_group_label>
    <arm_group_label>Part II, Cohort H (Pembro + I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_label>Part II, Cohort G (C + Pe With/without Pembro)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
    <arm_group_label>Part II, Cohort G (C + Pe With/without Pembro)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort D (Pembro + Ipilimumab [I])</arm_group_label>
    <arm_group_label>Part II, Cohort H (Pembro + I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Orally (po) daily (QD)</description>
    <arm_group_label>Part I, Cohort E (Pembro + Erlotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>po QD</description>
    <arm_group_label>Part I, Cohort F (Pembro + Gefitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IIIb/IV NSCLC

          -  Disease progression &gt;1 year after completing adjuvant therapy for Stage I-IIIA
             disease and no systemic therapy for the recurrent disease

          -  Resolution of any toxic effects (excepting alopecia) of the most recent therapy

          -  At least one radiographically measurable lesion

          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Status scale

          -  Female participants of reproductive potential must not be pregnant (negative urine or
             serum human chorionic gonadotropin test within 72 hours of study start)

          -  Female and male participants of reproductive potential must agree to use adequate
             contraception throughout the study period and for up to 120 days after the last dose
             of study therapy and for up to 180 days after the last dose of chemotherapeutic
             agents or tyrosine kinase inhibitors

        Exclusion Criteria:

          -  Currently participating or has participated in a study of an investigational agent or
             using an investigational device within 4 weeks of administration of pembrolizumab

          -  Expected to require any other form of antineoplastic therapy while on study

          -  Is on chronic systemic steroid therapy or on any other form of immunosuppressive
             medication

          -  Has received a live-virus vaccination within 30 days of planned treatment start

          -  Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI)
             obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)

          -  History of a hematologic malignancy, primary brain tumor or sarcoma, or of another
             primary solid tumor, unless the participant has undergone potentially curative
             therapy with no evidence of that disease for 5 years

          -  Active central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             (replacement therapies for hormone deficiencies are allowed)

          -  Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or
             PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other
             immuno-regulatory receptors or mechanisms

          -  Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery
             within 3 weeks of the first dose of study medication

          -  Radiation therapy to lung &gt;30 Gy within 6 months of first dose of study medication

          -  Prior tyrosine kinase inhibitor therapy or palliative radiation within 7 days of
             first dose of study medication

          -  Active infection requiring therapy

          -  History of Human Immunodeficiency Virus (HIV)

          -  Active Hepatitis B or C

          -  Symptomatic ascites or pleural effusion

          -  Interstitial lung disease or pneumonitis requiring oral or IV glucocorticoids

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study

          -  Psychiatric disorders and substance (drug/alcohol) abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0018)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0010)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0019)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0017)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0002)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0016)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0005)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0023)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0055)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0056)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0021)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0013)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0009)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0015)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0004)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0006)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0007)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0003)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0053)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0052)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corp.</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Hua Su</last_name>
      <phone>886-2-66316000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 26, 2016</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>PD1</keyword>
  <keyword>Programmed Cell Death-1</keyword>
  <keyword>Programmed Cell Death 1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
